- OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay
May 11, 2026 · businesswire.com
BOSTON--(BUSINESS WIRE)--OM1 helped power a 650,000-patient real-world evidence study supporting FDA approval of Hologic's Aptima HPV Assay for cervical cancer screening.
- OM1 SUPPORTS 650,000 PATIENT REAL-WORLD REGULATORY SUBMISSION FOR FDA APPROVAL OF HOLOGIC'S APTIMA HPV ASSAY
May 11, 2026
BOSTON--(BUSINESS WIRE)--OM1 HELPED POWER A 650,000-PATIENT REAL-WORLD EVIDENCE STUDY SUPPORTING FDA APPROVAL OF HOLOGIC'S APTIMA HPV ASSAY FOR CERVICAL CANCER SCREENING.
- CIBRA Capital Buys Stake in Allied Gold Stock
Apr 27, 2026
Amid the raging gold bull market, CIBRA Capital disclosed a new position in Allied Gold Corporation(NYSE:AAUC)on April 24, 2026. However, this may not have been a vote of confidence in Allied’s future growth, but a short-term arbitrage bet following an acquisition offer.
What happened
According to a recent SEC filing dated April 24, 2026, CIBRA Capital Ltd established a new position in Allied Gold Corporation by purchasing 423,652 shares. The estimated transaction value, calculated using the average unadjusted closing price for the first quarter, was $12.8 million. The market value of the stake was $13.1 million at the end of the quarter.
What else to know
This is a new position for the fund and now represents 6.3% of CIBRA Capital Ltd’s 13F reportable AUM. Top holdings after the filing:
NASDAQ: FOLD: $24.4 million (11.8% of AUM) NYSE: SEE: $21.6 million (10.4% of AUM) NYSE: TXNM: $16.6 million (8.0% of AUM) NASDAQ: MASI: $16.1 million (7.8% of AUM) NASDAQ: HOLX: $15.8 million (7.6% of AUM) As of April 23, 2026, shares were trading at $31.81, up 174.7% over the past year and outperforming the S&P 500 by 142.5 percentage points.
Company overview
Metric Value Market capitalization $4.0 billion Revenue (TTM) $1.33 billion Net income (TTM) $3.3 million Price (as of market close April 23, 2026) $31.81
Company snapshot
Produces and sells gold and silver, with principal revenue derived from mining operations in Mali, Côte d'Ivoire, and Ethiopia. Operates an integrated mining business model, generating income through exploration, extraction, and the sale of precious metals. Serves a global customer base of commodity buyers and refiners seeking gold and silver supply.
The company is a Canadian-based gold producer with a diversified portfolio of mining assets across Africa, focusing on established and emerging gold regions to support growth and resilience in fluctuating commodity cycles.
What this transaction means for investors
CIBRA Capital’s new purchase of Allied Gold shares appears to be a classic arbitrage trade. On Jan. 26, 2026, Allied Gold announced it had reached an agreement to be acquired by Zijin Gold International. This was an all-cash offer representing about 27% premium to Allied Gold’s 30-day volume-weighted average price.
The stock continued to trade at a discount to the offer after the announcement. CIBRA clearly saw an opportunity to buy a position and realize a profit once the deal closed and Allied shareholders were issued in cash the full value of the offer. Allied Gold shareholders approved Zijin’s offer on March 31, with completion expected by the end of April.
Story Continues
Gold stocks have had a great run the past few years. But overall, this appears to be a pure arbitrage trade to capture the difference between the share price and Zijin’s offer, rather than a long-term investment betting on further upside in Allied Gold stock.
Should you buy stock in Allied Gold right now?
Before you buy stock in Allied Gold, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Allied Gold wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 27, 2026.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Masimo and TXNM Energy, Inc. The Motley Fool has a disclosure policy.
CIBRA Capital Buys Stake in Allied Gold Stock was originally published by The Motley Fool
View Comments
- CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Apr 25, 2026
Key Points
Increased Amicus Therapeutics stake by 1,476,861 shares; estimated trade size $21.17 million (based on average price from January to March 2026) Quarter-end value of the position rose by $21.40 million, a figure reflecting both trading activity and share price movement Transaction equated to a 10.2% change in reportable assets under management (AUM) Post-trade, CIBRA Capital holds 1,687,661 shares valued at $24.40 million The position now represents 11.78% of the fund’s AUM, which makes it the top holding10 stocks we like better than Amicus Therapeutics ›
CIBRA Capital Ltd disclosed a buy of 1,476,861 shares of Amicus Therapeutics(NASDAQ:FOLD) in its April 24, 2026, SEC filing, an estimated $21.17 million trade based on quarterly average pricing.
Increased Amicus Therapeutics stake by 1,476,861 shares; estimated trade size $21.17 million (based on average price from January to March 2026)Quarter-end value of the position rose by $21.40 million, a figure reflecting both trading activity and share price movementTransaction equated to a 10.2% change in reportable assets under management (AUM)Post-trade, CIBRA Capital holds 1,687,661 shares valued at $24.40 millionThe position now represents 11.78% of the fund’s AUM, which places it outside the fund’s top five holdings
What happened
According to its SEC filing dated April 24, 2026, CIBRA Capital Ltd increased its holding in Amicus Therapeutics by 1,476,861 shares during the first quarter. The estimated transaction value was $21.17 million, calculated using the average closing price for the quarter. The value of the position at quarter-end rose by $21.40 million, which reflects both the new shares acquired and the underlying share price appreciation.
What else to know
This was a buy; the Amicus Therapeutics position now accounts for 11.78% of CIBRA Capital’s 13F reportable AUMTop five holdings post-filing:
NASDAQ: FOLD: $24.40 million (11.78% of AUM)NYSE:SEE: $21.64 million (10.4% of AUM)NYSE:TXNM: $16.57 million (8.0% of AUM)NASDAQ:MASI: $16.08 million (7.8% of AUM)NASDAQ:HOLX: $15.80 million (7.6% of AUM)As of April 23, 2026, Amicus Therapeutics shares were priced at $14.46The stock posted a 103.7% one-year total return, outperforming the S&P 500 by 71.43 percentage points
Company Overview MetricValuePrice (as of market close 2026-04-23)$14.46Market Capitalization$4.54 billionRevenue (TTM)$634.21 millionNet Income (TTM)($27.11 million)
Company Snapshot
Key products include Galafold for Fabry disease and AT-GAA for Pompe disease, alongside pipeline candidates targeting rare genetic disorders.Revenue is primarily generated through the commercialization of proprietary therapies for rare diseases, leveraging internal R&D and strategic partnerships.The company targets adult patients with rare metabolic and genetic conditions, focusing on underserved populations with limited treatment options.
Amicus Therapeutics, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of therapies for rare diseases. With a focus on precision medicines and a robust pipeline, the company leverages scientific expertise and strategic collaborations to address unmet medical needs. Its established commercial presence and targeted approach provide a competitive edge in the rare disease therapeutics market.
What this transaction means for investors
Last December, BioMarin Pharmaceutical(NASDAQ:BMRN) offered to acquire Amicus Therapeutics for $14.50 per share in cash. We don’t know exactly when CIBRA Capital bought heaps of Amicus shares during the first quarter. At the beginning of January, the stock was trading for around $14.30 per share. If CIBRA bought around that time, it stands to earn $0.20 per share if the transaction completes as anticipated.
Buying a stock priced slightly below its anticipated acquisition price is called merger arbitrage. This biotech deal is about as certain to complete as intended as deals get. Last December, the Boards of Directors of both companies unanimously recommended Amicus’ shareholders vote to adopt the agreement. Federal regulators rarely stick their noses into M&A deals for companies such as Amicus, which currently markets recently launched rare disease drugs.
While merger arbitrage is not an unusual practice for large firms, making Amicus CIBRA’s largest position was a bold move. If the deal doesn’t complete as expected, Amicus’ stock price could fall hard.
Should you buy stock in Amicus Therapeutics right now?
Before you buy stock in Amicus Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amicus Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 25, 2026.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Masimo and TXNM Energy, Inc. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Apr 25, 2026
CIBRA Capital Ltd disclosed a buy of 1,476,861 shares of Amicus Therapeutics(NASDAQ:FOLD) in its April 24, 2026, SEC filing, an estimated $21.17 million trade based on quarterly average pricing.
Increased Amicus Therapeutics stake by 1,476,861 shares; estimated trade size $21.17 million (based on average price from January to March 2026) Quarter-end value of the position rose by $21.40 million, a figure reflecting both trading activity and share price movement Transaction equated to a 10.2% change in reportable assets under management (AUM) Post-trade, CIBRA Capital holds 1,687,661 shares valued at $24.40 million The position now represents 11.78% of the fund’s AUM, which places it outside the fund’s top five holdings
What happened
According to its SEC filing dated April 24, 2026, CIBRA Capital Ltd increased its holding in Amicus Therapeutics by 1,476,861 shares during the first quarter. The estimated transaction value was $21.17 million, calculated using the average closing price for the quarter. The value of the position at quarter-end rose by $21.40 million, which reflects both the new shares acquired and the underlying share price appreciation.
What else to know
This was a buy; the Amicus Therapeutics position now accounts for 11.78% of CIBRA Capital’s 13F reportable AUM Top five holdings post-filing:
NASDAQ: FOLD: $24.40 million (11.78% of AUM) NYSE:SEE: $21.64 million (10.4% of AUM) NYSE:TXNM: $16.57 million (8.0% of AUM) NASDAQ:MASI: $16.08 million (7.8% of AUM) NASDAQ:HOLX: $15.80 million (7.6% of AUM) As of April 23, 2026, Amicus Therapeutics shares were priced at $14.46 The stock posted a 103.7% one-year total return, outperforming the S&P 500 by 71.43 percentage points
Company Overview
Metric Value Price (as of market close 2026-04-23) $14.46 Market Capitalization $4.54 billion Revenue (TTM) $634.21 million Net Income (TTM) ($27.11 million)
Company Snapshot
Key products include Galafold for Fabry disease and AT-GAA for Pompe disease, alongside pipeline candidates targeting rare genetic disorders. Revenue is primarily generated through the commercialization of proprietary therapies for rare diseases, leveraging internal R&D and strategic partnerships. The company targets adult patients with rare metabolic and genetic conditions, focusing on underserved populations with limited treatment options.
Amicus Therapeutics, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of therapies for rare diseases. With a focus on precision medicines and a robust pipeline, the company leverages scientific expertise and strategic collaborations to address unmet medical needs. Its established commercial presence and targeted approach provide a competitive edge in the rare disease therapeutics market.
Story Continues
What this transaction means for investors
Last December, BioMarin Pharmaceutical(NASDAQ:BMRN) offered to acquire Amicus Therapeutics for $14.50 per share in cash. We don’t know exactly when CIBRA Capital bought heaps of Amicus shares during the first quarter. At the beginning of January, the stock was trading for around $14.30 per share. If CIBRA bought around that time, it stands to earn $0.20 per share if the transaction completes as anticipated.
Buying a stock priced slightly below its anticipated acquisition price is called merger arbitrage. This biotech deal is about as certain to complete as intended as deals get. Last December, the Boards of Directors of both companies unanimously recommended Amicus’ shareholders vote to adopt the agreement. Federal regulators rarely stick their noses into M&A deals for companies such as Amicus, which currently markets recently launched rare disease drugs.
While merger arbitrage is not an unusual practice for large firms, making Amicus CIBRA’s largest position was a bold move. If the deal doesn’t complete as expected, Amicus’ stock price could fall hard.
Should you buy stock in Amicus Therapeutics right now?
Before you buy stock in Amicus Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amicus Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 25, 2026.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Masimo and TXNM Energy, Inc. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD) was originally published by The Motley Fool
View Comments
- New Evidence Backs Hologic’s AI-Powered Mammography Technology for Detecting Challenging Cancers
Apr 20, 2026
Results highlight AI’s potential to aid radiologists in identifying diverse breast cancer subtypes, including invasive lobular cancer
Results highlight AI’s potential to aid radiologists in identifying diverse breast cancer subtypes, including invasive lobular cancer
MARLBOROUGH, Mass., April 20, 2026--(BUSINESS WIRE)--New research on Hologic’s AI-driven breast cancer detection technologies, including a study focused on invasive lobular cancer, was presented at the Society of Breast Imaging (SBI) Symposium over the weekend in Seattle, Washington.
"Invasive lobular cancers are more challenging to detect on a mammogram because of their unique characteristics," said Mark Horvath, President of Breast & Skeletal Health Solutions at Hologic. "In the study, AI maintained high sensitivity for flagging these cancers, including some that had been interpreted as negative at a prior screening. These data add to a growing body of evidence that AI can act as a powerful supportive tool for radiologists as they review the full spectrum of breast cancers."
In this retrospective, single-center study, researchers at Massachusetts General Hospital in Boston reviewed invasive lobular cancer cases diagnosed over a 10-year period and grouped them into two categories: those detected by a radiologist during a routine screening exam (195 total) and "false negatives" that were diagnosed within a year of a routine screening exam initially interpreted as negative (44 total). Researchers then used Hologic’s Genius AI® Detection solution to retrospectively analyze all 239 cases. In this cohort, the technology identified and correctly localized close to 90% of the confirmed invasive lobular cancers.1
New research suggests that, on average, 1 in 20 women worldwide will be diagnosed with breast cancer in their lifetime and, that if current rates continue, by 2050 there will be 3.2 million new breast cancer cases and 1.1 million breast cancer-related deaths per year.2 About 10-15% of all breast cancers are invasive lobular cancers,3 while ductal cancers that originate in the milk ducts of the breast — such as invasive ductal carcinoma and ductal carcinoma in situ — occur more commonly. Invasive lobular cancer arises in the milk-producing glands (lobules) of the breast and, because of its unique biology and tendency to grow in a linear pattern, it may be more challenging to see on mammography. This may lead to later detection and a more advanced stage at diagnosis.
The AI algorithm also identified 43% of the invasive lobular cancer cases initially interpreted during routine screening as negative.1 Of note, as a retrospective analysis at a single institution, the study did not evaluate how use of AI in real time clinical practice would affect recall rates, biopsy outcomes or patient management.
Story Continues
Also at the Society of Breast Imaging Symposium, Hologic hosted a lunch and learn discussion with breast imaging experts focused on implementation of 3DQuorum® imaging technology, which uses AI to reduce the number of 3D imaging "slices" radiologists need to review without compromising image quality, sensitivity or accuracy.4,5
Study Limitations
The MGH study did not assess false-positive rates, recall rates or biopsy outcomes, and its single-center design may limit generalizability. AI performance was evaluated retrospectively and did not influence real-time radiologist decision-making; therefore, the observed gains represent a theoretical upper bound rather than a measured clinical impact. Additionally, the cohort included only patients with invasive lobular cancer, precluding comparison with other histologic subtypes.
About Genius AI Detection
Hologic’s Genius AI Detection solution is an innovative mammography screening technology designed to locate lesions likely to represent breast cancer. Suspicious areas are highlighted at radiologists’ workstations for concurrent reading to support smart, decisive interpretation. Hologic's deep learning algorithm is fed by the accumulation of a large, diverse patient base, providing rich insight and intelligence. For more information, please visit Genius AI Detection Technology.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X,Instagram and YouTube.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Hologic, The Science of Sure, Genius AI and 3DQuorum are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
References
1. Lamb LR, Kim H, Do S, Bahl M. Artificial intelligence for the detection of invasive lobular carcinoma on screening digital breast tomosynthesis. Oral presentation, Society of Breast Imaging Symposium, Seattle, WA, April 2026.
2. Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nature Medicine. 2025;31(4). doi:https://doi.org/10.1038/s41591-025-03502-3.
3. DePolo J. Invasive Lobular Carcinoma (ILC). www.breastcancer.org. https://www.breastcancer.org/types/invasive-lobular-carcinoma.
4. Report: CSR-00116.
5. FDA Submission: P080003/S008.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260420522939/en/
Contacts
Media Contact:
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
View Comments
- New Evidence Backs Hologic's AI-Powered Mammography Technology for Detecting Challenging Cancers
Apr 20, 2026 · businesswire.com
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #WomensHealth--Research presented at the Society of Breast Imaging (SBI) Symposium backs Hologic AI-powered mammography technology for detecting challenging cancers.
- NEW EVIDENCE BACKS HOLOGIC'S AI-POWERED MAMMOGRAPHY TECHNOLOGY FOR DETECTING CHALLENGING CANCERS
Apr 20, 2026
MARLBOROUGH, MASS.--(BUSINESS WIRE)-- #WOMENSHEALTH--RESEARCH PRESENTED AT THE SOCIETY OF BREAST IMAGING (SBI) SYMPOSIUM BACKS HOLOGIC AI-POWERED MAMMOGRAPHY TECHNOLOGY FOR DETECTING CHALLENGING CANCERS.
- TD Cowen Cuts TPG PT Amid Q1 Preview for Asset Managers
Apr 15, 2026
TPG Inc. (NASDAQ:TPG) is included among the 14 Value Stocks with Highest Dividends.TD Cowen Cuts TPG PT Amid Q1 Preview for Asset Managers
On April 9, TD Cowen analyst Bill Katz lowered the firm’s price recommendation on TPG Inc. (NASDAQ:TPG) to $41 from $49. It reiterated a Hold rating on the shares. The firm adjusted targets across asset managers, broker-dealers, and exchanges as part of its Q1 preview.
On April 5, Bank of America analyst Craig Siegenthaler lowered the firm’s price objective on TPG to $60 from $69 and maintained a Buy rating. The firm reduced targets across the asset managers group as part of a Q1 preview. It said macro indicators point to a “challenging” first half of 2026, according to a research note. It also noted that no companies in the group appear positioned for strong Q1 results.
In another update, on April 7, Hologic, Inc. announced the completion of its acquisition by funds managed by Blackstone Inc. and TPG in a deal valued at up to $79 per share, taking the company private. The transaction includes minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC Private Limited. In connection with the deal, the company named José E. Almeida as Chief Executive Officer, effective immediately.
TPG Inc. (NASDAQ:TPG) is an alternative asset management company. It invests across private equity, impact, credit, real estate, and market solutions.
While we acknowledge the potential of TPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 NASDAQ Stocks with Highest Dividends and 15 Cash-Rich Dividend Stocks to Invest In Right Now
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Software sting: Tech share of direct lending deals drops in Q1 – US Private Credit Monitor
Apr 14, 2026
The often steady sectoral mix of direct lending deals shifted notably in the first quarter, with Healthcare displacing Technology as the sector receiving the largest share of direct lending deployment, according to LCD data.
The latest US Private Credit Monitor shows that healthcare deals made up 22% of direct lending issuance YTD through March, up from 18% in 2025, while Tech’s share slipped to 14% YTD from 18% in 2025.
More broadly, direct lending deal volume rose quarter-over-quarter and surged 26% year-over-year, propped up by larger transactions as deal count trailed last year’s pace.
New-issue sponsor-backed loan volume financed in the BSL market sharply outpaced direct lending volume in the first quarter, boosted by a handful of mega-deals like Electronic Arts and Hologic.
Direct lending takeouts of BSL deals exceeded BSL takeouts of private credit financings in Q1, though the gap narrowed from the prior quarter, as the two were nearly even.
The full March US Private Credit Monitor is available for download to all here.
Sign up for The Credit Pitch
Weekly coverage of US and European loans, bonds, private credit, and more.
Subscribe
This article originally appeared on PitchBook News
View Comments
